Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Rein Therapeutics, Inc. incurred loan of $2,500,000 with Funicular Funds, LP at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.
- Instrument
- loan
- Principal
- $2,500,000
- Counterparty
- Funicular Funds, LP
- Rate
- 20% original issue discount
- Maturity
- the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions
- Event
- incurrence
Exact text from the filing
the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Rein Therapeutics, Inc. entered into Purchase Agreement with Funicular Funds, LP valued at original principal amount of $2,500,000 (effective 2026-01-15).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Funicular Funds, LP
- Value
- original principal amount of $2,500,000
- Effective
- 2026-01-15
Exact text from the filing
On January 15, 2026, Rein Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Funicular Funds, LP, a Delaware limited partnership managed by Cable Car Capital, LP (“Funicular”), pursuant to which the Company issued and sold to Funicular, in a private placement, an unsecured promissory note, dated January 15, 2026, in the original principal amount of $2,500,000 (the “Note”).
View on SEC.gov